Esperion Q1 net loss $61.7M; US product revenue +27% to $17M; Currax partnership

Esperion Therapeutics, Inc.

2023-Q1 EPS reported -$0.79 revenue$24,329,000

Total revenue $24.3M (+29% YoY); US net product revenue $17.0M (+27%); retail Rx equivalents +15% YoY.
Net loss $61.7M vs $56.7M loss in Q1 2022; diluted EPS loss $0.79 vs $0.93.
Pay-for-performance commercial partnership with Currax Pharmaceuticals to double promotional footprint.
Regulatory filings for bempedoic acid label update expected in 1H 2023 in U.S. and Europe.
Full-year 2023 operating expense guidance reaffirmed at $225-245M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Esperion Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $24.3 million, net income $61.7 million, EPS $0.79. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $24.3 million
Net income: $61.7 million
EPS: $0.79
Guidance: reaffirmed
Result: reported results

Exact text from the filing

the clinical trials comprising the CLEAR program, the Company’s pipeline, and information about cardiometabolic disease. First Quarter 2023 Financial Results Total revenue was $24.3 million, compared to $18.8 million for the comparable period in 2022, an increase of 29%. U.S. net product revenue was $17.0 million, compared to $13.4 million for the comparable period

View on SEC.gov

Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-016620

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.